Table 2.
Eligible studies for the meta-analysis and their study characteristics.
| Author | Year | Sample Size | Age, Years, Median (Range) | Pathological Stage | Median Follow-Up (Range) | HR, Multivariate Analysis (CI) | NLR Cut-Off | p-Value |
|---|---|---|---|---|---|---|---|---|
| Viers et al. [33] | 2014 | 899 | 69 (62–76) | T ≤ 1–T4, Nx, N0–N3 | 10.9 years (8.3–13.9) | Recurrence: HR 1.04 (1.01–1.08) | NLR > 2.7 | p = 0.02 |
| Hermanns et al. [32] | 2014 | 424 | 70.1 (60.6–76.3) | T0–T4, Ta, Tis, Nx, N0, N+ | 58.4 months (21.3–94.5) | Recurrence: HR 1.49 (1.12–2.00) | NLR ≥ 3 | p = 0.007 |
| Bhindi et al. [20] | 2016 | 418 | 70 (61–76) | T0– T4, Ta, Tis, N0, N+, Nx | 40 months (14–72) | RFS: HR 1.52 (1.17–1.98) | NLR < 2.9 | p = 0.002 |
| Morizawa et al. [22] | 2016 | 110 | 72 (65–76) | T0–T4, N+ | 37.5 months (11–65) | RFS: HR 2.6 (1.1–6.0) | NLR < 2.6 | p = 0.02 |
| D’Andrea et al. [21] | 2017 | 4198 | 67 (60–73) | T0–T4, Ta, Tis; N+ | not reported | RFS: HR 1.2 (1.1–1.3) | NLR < 2.7 | p < 0.001 |
| Tan et al. [36] | 2017 | 84 | 67 (37–82) | T1–T4, N+ | 30.1 months (3.2–161.7) | Recurrence: HR 6.999 (1.712–28.606) | NLR ≥ 2.7 | p = 0.007 |
| Mari et al. [45] | 2021 | 255 | 79 (75–83) | T1–T4, Nx, N0–N3 | Not reported | Recurrence: HR 1.13 (0.96–1.32) | NLR > 3 | p = 0.14 |
HR = hazard ratio, CI = confidence interval, NLR = neutrophil-to-lymphocyte ratio, RFS = recurrence-free survival.